Editas Medicine (EDIT)
(Real Time Quote from BATS)
$3.06 USD
-0.02 (-0.65%)
Updated Nov 3, 2025 09:38 AM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EDIT 3.06 -0.02(-0.65%)
Will EDIT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for EDIT
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
Other News for EDIT
Stochastic Buy Signal appears for EDIT after 2.33% move
Gene editing therapy companies rise on word of streamlined FDA approval process
FDA to speed up gene editing therapy approvals, Bloomberg reports
FDA to speed up gene editing therapy approvals, Bloomberg reports
EDIT forms MACD Bearish Centerline Cross on October 30